Protica Bio combines proteomics and machine learning to identify predictive markers of response and novel drug targets for immunotherapy, particularly immune checkpoint inhibitors in solid tumors. This approach addresses the low response rates of current therapies by enabling personalized treatment strategies and informed therapeutic decision-making.
Funding
Funding not disclosed
Founders
Product
Problem
Response rates to immune checkpoint inhibitors (ICI) in solid tumors remain significantly low. Identifying predictive markers of response and novel drug targets is critical for improving the effectiveness of immunotherapy and enabling personalized treatment strategies.
Solution
Protica Bio leverages proteomics and computational biology to identify predictive biomarkers and novel drug targets for cancer immunotherapy. The company's platform combines state-of-the-art proteomics technologies with machine learning to analyze the tumor proteome in an unbiased manner. This approach enables the identification of resistance mechanisms, novel cancer regulators, and real-time biological signals that predict treatment response. The platform delivers protein coverage, revealing insights into tumor cell biology that can be used to make cancer treatments more effective and personalized.
Target Audience
The primary target audience includes researchers and pharmaceutical companies focused on developing and personalizing cancer immunotherapy treatments, particularly immune checkpoint inhibitors for solid tumors.
Features
- Proprietary proteomics platform for in-depth analysis of the tumor proteome
- Machine learning algorithms to identify predictive markers of response to immunotherapy
- Identification of novel drug targets for combination therapies with immune checkpoint inhibitors
- Actionable proteomic insights into tumor cell biology